Navigation Links
Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
Date:7/2/2008

REDWOOD CITY, Calif., July 2 /PRNewswire/ -- Pearl Therapeutics, Inc., a biopharmaceutical company developing products for major respiratory diseases, today announced that it has completed the closing of an $18 million round of financing. This financing was executed as an extension to its first venture financing, which closed in May 2007. Participating in the internal round were Pearl's existing investors Clarus Ventures, New Leaf Ventures, 5AM Ventures and Nektar Therapeutics. In total, Pearl has raised $36.4 million of venture and other funding.

"We have worked hard over the past year to establish the company, build the team, and advance our product pipeline. This follow-on financing signifies the confidence and enthusiasm of our investors, and we are delighted with their continued support. This additional capital will allow us to broaden and progress development efforts on our products and delivery platform," said Adrian Smith, President, and co-founder of Pearl.

"Pearl has been successful at attracting some of the top respiratory product development talent in the world, and has delivered on its commitments. We fully support the team in moving ahead with its product and platform plan," said Jim Young, PhD, Chairman of the Board of Directors of Pearl, and Venture Partner at 5AM Ventures.

About Pearl Therapeutics, Inc. (http://www.pearltherapeutics.com)

Pearl Therapeutics is developing a pipeline of advanced respiratory products that will offer patients and their healthcare providers a choice of formulations and dosage strengths better suited to their needs. Pearl's products will afford multiple health benefits compared to current treatment options and will be available in familiar and widely used dosage forms to enhance compliance. The company has licensed advanced particle technology from Nektar Therapeutics and is developing it further for application in selected fields.

Founded in 2006, Pearl Therapeutics is privately held and backed by Clarus Ventures, New Leaf Ventures, 5AM Ventures, and Nektar Therapeutics.


'/>"/>
SOURCE Pearl Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. String of fullerene pearls
3. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
4. MUSCs Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr.
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... 18, 2017 , ... A number of new instruments have recently emerged to ... the Protein and Cell Analysis Education Webinar Series , will focus on advances ... current and future applications. , Many flow cytometers have unique capabilities and the ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics ... The move comes after the company changed focus to making analytical tools for ... and our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart ...
(Date:4/19/2017)... ... April 19, 2017 , ... ThermaGenix, the PCR Improvement ... adds to several other early achievements at ThermaGenix, including the business formation and ... , ThermaGenix will use proceeds from the Series A-1 round to:, ...
(Date:4/19/2017)... Linda, Ca (PRWEB) , ... April 19, 2017 ... ... University Virtual Event, which makes educational webinars accessible to novices as well ... impact of preanalytical variables of commonly performed coagulation screening tests. , Hemostasis ...
Breaking Biology Technology:
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):